DUBLIN–(BUSINESS WIRE)–The “Stem Cell Market – Growth, Trends, COVID-19 Impact, and Forecasts (2021 – 2026)” report has been added to ResearchAndMarkets.com’s offering.
The stem cell market is estimated to be valued at USD 14.7 billion in 2020 and is expected to reach approximately USD 26.40 billion in 2026, registering a CAGR of nearly 10.24% during the forecast period.
The growth of the market is attributed to the rising number of clinical trials and the growing adoption of stem cell therapies globally.
In the context of COVID-19, government organizations in various countries, research institutes, and many biotech and pharmaceutical firms are focusing on effective and rapid technologies for the fast diagnosis of COVID-19. According to a 2020 research article published in the scientific journal Aging and Disease (2020), mesenchymal stem cells are a safe and effective approach to the treatment of COVID-19. At least 10 projects have been registered in the official international registry for clinical trials, implicating the use of mesenchymal stem cells to patients with Corona virus pneumonia. However, it is still at an initial stage of study in relation to the market studied.
Stem cells are majorly used in regenerative medicine, especially in the field of dermatology. However, oncology is expected to grow at the highest growth rate, due to a large number of pipeline products present for the treatment of tumors or cancers. With the increase in the number of regenerative medicine centers, the stem cell market is also expected to increase in the future.
Key Market Trends
Oncology Disorders Segment is Expected to Exhibit Fastest Growth Rate Over the Forecast Period
The global cancer burden has been increasing, and thus, cancer therapies must be modified according to regional and national priorities. According to the World Cancer Research Fund, in 2018, there were an estimated 18 million cancer cases around the world. According to the World Health Organization (WHO), cancer is the second-leading cause of death across the world, with an estimated number of 9.6 million deaths in 2018, hence, accounting for nearly one in six deaths.
Bone marrow transplant or stem cell transplant is a treatment for some types of cancer, like leukemia, multiple myeloma, neuroblastoma, or some types of lymphoma. For cancer treatments, both autologous and allogeneic stem cell transplants are done. Autologous transplants are preferred, in the case of leukemias, lymphomas, multiple myeloma, testicular cancer, and neuroblastoma.
The major disadvantage associated with autologous stem cell transplants in cancer therapy is that, cancer cells sometimes also get collected, along with stem cells, which may further put it back into the body during the therapy.
In case of allogeneic stem cell transplants, the donor can often be asked to donate more stem cells or even white blood cells, as per the requirement, and stem cells from healthy donors are free of cancer cells. However, the transplanted donor stem cells could die or be destroyed by the patient’s body, before settling in the bone marrow.
Moreover, due to the growing focus of stem cell-based research and the rising demand of novel treatments, several companies, such as Stemline Therapeutics, have been focusing on developing technologies and treatments to attack cancer cells, which may help the market to grow. However, owing to the COVID 19 pandemic, the detection and treatment of the new cancer cases is impended and is expected to slightly impact the segment growth in the year.
The stem cell market is highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market.
The presence of major market players, such as Thermo Fisher Scientific (Qiagen NV), Sigma Aldrich (A Subsidiary of Merck KGaA), Becton, Dickinson and Company, and Stem Cell Technologies, is in turn, increasing the overall competitive rivalry in the market.
The product advancements and improvement in stem cell technology by the major players are increasing the competitive rivalry.
Key Topics Covered:
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increased Awareness about Umbilical Stem Cell
4.2.2 Rising R&D Initiatives to Develop Stem Cell Therapies and Increasing Approvals for Clinical Trials in Stem Cell Research
4.2.3 Growing Demand for Regenerative Treatment Option
4.3 Market Restraints
4.3.1 Expensive Procedures
4.3.2 Regulatory Complications
4.3.3 Ethical and Moral Framework
4.4 Industry Attractiveness- Porter’s Five Forces Analysis
5 MARKET SEGMENTATION
5.1 By Product Type
5.1.1 Adult Stem Cell
5.1.2 Human Embryonic Cell
5.1.3 Pluripotent Stem Cell
5.1.4 Other Product Types
5.2 By Application
5.2.1 Neurological Disorders
5.2.2 Orthopedic Treatments
5.2.3 Oncology Disorders
5.2.4 Injuries and Wounds
5.2.5 Cardiovascular Disorders
5.2.6 Other Applications
5.3 By Treatment Type
5.3.1 Allogeneic Stem Cell Therapy
5.3.2 Auto logic Stem Cell Therapy
5.3.3 Syngeneic Stem Cell Therapy
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Smith & Nephew
6.1.2 PLURISTEM THERAPEUTICS INC.
6.1.3 Thermo Fisher Scientific
6.1.4 Qiagen NV
6.1.5 Merck KGaA (Sigma Aldrich)
6.1.6 Becton, Dickinson and Company
6.1.7 Stem Cell Technologies Inc.
6.1.8 ThermoGenesis Holdings, Inc.
6.1.9 Astellas Pharma, Inc.
6.1.10 Cellular Engineering Technologies
6.1.11 Takara Bio Group
6.1.12 Osiris Therapeutics
6.1.14 Holostem Terapie Avanzate S.r.l
7 Market Opportunities and Future Trends
For more information about this report visit https://www.researchandmarkets.com/r/oz7guq
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900